Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.67 |
| ▸ | CTSS | P25774 | 5/20 | 0.67 |
| ▸ | CTSL | P07711 | 5/20 | 0.67 |
| ▸ | CTSV | O60911 | 3/20 | 0.67 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | HTRA1 | Q92743 | 4/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4214766 | 1.00 | CTSK (0.67) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL5941431 | 1.00 | CTSK (0.67) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL4219845 | 1.00 | CTSK (0.67) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL8349497 | 0.92 | CTSK (0.57) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL8348351 | 0.92 | CTSS (0.59) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL4213137 | 0.90 | CTSK (0.56) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL4213141 | 0.90 | CTSK (0.56) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL5942062 | 0.90 | CTSK (0.56) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL4213145 | 0.90 | CTSK (0.56) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL4230211 | 0.90 | CTSK (0.55) | CTSKCTSSCTSLCTSVCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885CTSL 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.